Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Dengue: knowledge gaps, unmet needs, and research priorities

Open access
Katzelnick, Leah C, Coloma, Josefina, Harris, Eva · 2017 · The Lancet Infectious Diseases

Abstract

Summary Dengue virus (DENV) is a mosquito-borne pathogen that causes up to ~100 million dengue cases each year, placing a major public health, social and economic burden on numerous low- and middle-income countries (LMICs). Major advances by scientists, vaccine developers, and affected communities are revealing new insights and enabling novel interventions and approaches to dengue prevention and control. Such research has highlighted further questions about both the basic understanding of dengue and efforts to develop new tools. We discuss existing approaches to dengue diagnostics, disease prognosis, surveillance, and vector control in LMICs as well as potential consequences of vaccine introduction. We also summarize current knowledge and recent insights into dengue epidemiology, immunology, and pathogenesis, and their implications for understanding natural infection and current and future vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(16)30473-x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 140

  1. Radke, 2012, Dengue outbreak in Key West, Florida, USA, 2009, Emerg Infect Dis, 18, 135, 10.3201/eid1801.110130 · DOI · Paper page
  2. Schaffner, 2014, Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future, Lancet Infect Dis, 14, 1271, 10.1016/S1473-3099(14)70834-5 · DOI · Paper page
  3. Shepard, 2014, Approaches to refining estimates of global burden and economics of dengue, PLoS Negl Trop Dis, 8, e3306, 10.1371/journal.pntd.0003306 · DOI
  4. Teoh, 2015, Early detection of dengue virus by use of reverse transcription-recombinase polymerase amplification, J Clin Microbiol, 53, 830, 10.1128/JCM.02648-14 · DOI
  5. Hunsperger, 2014, Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody, PLoS Negl Trop Dis, 8, e3171, 10.1371/journal.pntd.0003171 · DOI · Paper page
  6. John, 2015, Biomarkers of severe dengue disease—a review, J Biomed Sci, 22, 83, 10.1186/s12929-015-0191-6 · DOI
  7. Wesolowski, 2015, Impact of human mobility on the emergence of dengue epidemics in Pakistan, Proc Natl Acad Sci USA, 112, 11887, 10.1073/pnas.1504964112 · DOI · Paper page
  8. Lozano-Fuentes, 2013, Cell phone-based system (Chaak) for surveillance of immatures of dengue virus mosquito vectors, J Med Entomol, 50, 879, 10.1603/ME13008 · DOI
  9. Morrison, 2010, Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission, PLoS Negl Trop Dis, 4, e670, 10.1371/journal.pntd.0000670 · DOI · Paper page
  10. Montoya, 2013, Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year, PLoS Negl Trop Dis, 7, e2357, 10.1371/journal.pntd.0002357 · doi:10.1371/journal.pntd.0002357
  11. Achee, 2015, A critical assessment of vector control for dengue prevention, PLoS Negl Trop Dis, 9, e0003655, 10.1371/journal.pntd.0003655 · DOI · Paper page
  12. Gubler, 2015, The partnership for dengue control—a new global alliance for the prevention and control of dengue, Vaccine, 33, 1233, 10.1016/j.vaccine.2015.01.002 · doi:10.1016/j.vaccine.2015.01.002
  13. George, 2015, Community-effectiveness of temephos for dengue vector control: a systematic literature review, PLoS Negl Trop Dis, 9, e0004006, 10.1371/journal.pntd.0004006 · DOI
  14. Hurst, 2010, Melanotaenia duboulayi influence oviposition site selection by Culex annulirostris (Diptera: Culicidae) and Aedes notoscriptus (Diptera: Culicidae) but not Culex quinquefasciatus (Diptera: Culicidae), Environ Entomol, 39, 545, 10.1603/EN09138 · DOI
  15. Winskill, 2015, Dispersal of engineered male Aedes aegypti mosquitoes, PLoS Negl Trop Dis, 9, 1, 10.1371/journal.pntd.0004156 · DOI
  16. Hoffmann, 2011, Successful establishment of wolbachia in aedes populations to suppress dengue transmission, Nature, 476, 454, 10.1038/nature10356 · DOI · Paper page
  17. Nguyen, 2015, Field evaluation of the establishment potential of wMelPop wolbachia in Australia and Vietnam for dengue control, Parasit Vectors, 8, 563, 10.1186/s13071-015-1174-x · DOI · Paper page
  18. Arunachalam, 2012, Community-based control of Aedes aegypti by adoption of eco-health methods in Chennai City, India, Pathog Glob Health, 106, 488, 10.1179/2047773212Y.0000000056 · DOI · Paper page
  19. Ferguson, 2015, Modeling the impact on virus transmission of wolbachia-mediated blocking of dengue virus infection of Aedes aegypti, Sci Transl Med, 7, 279ra37, 10.1126/scitranslmed.3010370 · DOI · Paper page
  20. Reiner, 2014, Socially structured human movement shapes dengue transmission despite the diffusive effect of mosquito dispersal, Epidemics, 6, 30, 10.1016/j.epidem.2013.12.003 · DOI
  21. Perkins, 2014, Theory and data for simulating fine-scale human movement in an urban environment, J R Soc Interface, 11, 20140642, 10.1098/rsif.2014.0642 · DOI
  22. Rabaa, 2013, Dengue virus in sub-tropical northern and central Viet Nam: population immunity and climate shape patterns of viral invasion and maintenance, PLoS Negl Trop Dis, 7, e2581, 10.1371/journal.pntd.0002581 · DOI
  23. van Panhuis, 2015, Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia, Proc Natl Acad Sci, 112, 13069, 10.1073/pnas.1501375112 · DOI · Paper page
  24. Cummings, 2009, The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling, PLoS Med, 6, e1000139, 10.1371/journal.pmed.1000139 · DOI · Paper page
  25. Rodríguez-Barraquer, 2014, Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control, Am J Epidemiol, 179, 353, 10.1093/aje/kwt256 · doi:10.1093/aje/kwt256
  26. Waggoner, 2016, Homotypic dengue virus reinfections in Nicaraguan children, J Infect Dis, 214, 968, 10.1093/infdis/jiw099 · DOI
  27. Duong, 2015, Asymptomatic humans transmit dengue virus to mosquitoes, Proc Natl Acad Sci, 112, 14688, 10.1073/pnas.1508114112 · DOI · Paper page
  28. Katzelnick, 2016, Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort, Proc Natl Acad Sci USA, 113, 728, 10.1073/pnas.1522136113 · DOI · Paper page
  29. Clapham, 2016, Dengue virus (DENV) neutralizing antibody kinetics in children after symptomatic primary and postprimary DENV infection, J Infect Dis, 213, 1428, 10.1093/infdis/jiv759 · doi:10.1093/infdis/jiv759
  30. Fox, 2014, Investigation of dengue and Japanese encephalitis virus transmission in Hanam, Vietnam, Am J Trop Med Hyg, 90, 892, 10.4269/ajtmh.13-0077 · doi:10.4269/ajtmh.13-0077
  31. Perkins, 2014, A review of transmission models of dengue: a quantitative and qualitative analysis of model features, 99
  32. Forshey, 2016, Incomplete protection against dengue virus type 2 re-infection in Peru, PLoS Negl Trop Dis, 10, e0004398, 10.1371/journal.pntd.0004398 · DOI
  33. Hadinegoro, 2015, Efficacy and long-term safety of a dengue vaccine in regions of endemic disease, N Engl J Med, 373, 1195, 10.1056/NEJMoa1506223 · DOI · Paper page
  34. Capeding, 2014, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial, Lancet, 384, 1358, 10.1016/S0140-6736(14)61060-6 · DOI · Paper page
  35. Villar, 2015, Efficacy of a tetravalent dengue vaccine in children in Latin America, N Engl J Med, 372, 113, 10.1056/NEJMoa1411037 · DOI · Paper page
  36. Coudeville, 2015, Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies, Vaccine, 34, 6417, 10.1016/j.vaccine.2015.11.023 · DOI
  37. Nisalak, 2003, Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999, Am J Trop Med Hyg, 68, 191, 10.4269/ajtmh.2003.68.191 · DOI · Paper page
  38. Balmaseda, 2006, Serotype-specific differences in clinical manifestations of dengue, Am J Trop Med Hyg, 74, 449, 10.4269/ajtmh.2006.74.449 · DOI · Paper page
  39. OhAinle, 2011, Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity, Sci Transl Med, 3, 114ra128, 10.1126/scitranslmed.3003084 · DOI · Paper page
  40. Bhoomiboonchoo, 2015, Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010, BMC Public Health, 15, 1, 10.1186/s12889-015-1590-z · doi:10.1186/s12889-015-1590-z
  41. Kochel, 2002, Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever, Lancet, 360, 310, 10.1016/S0140-6736(02)09522-3 · doi:10.1016/s0140-6736(02)09522-3
  42. Olkowski, 2013, Reduced risk of disease during postsecondary dengue virus infections, J Infect Dis, 208, 1026, 10.1093/infdis/jit273 · DOI
  43. Guirakhoo, 2002, Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates, Virology, 298, 146, 10.1006/viro.2002.1462 · DOI
  44. VanBlargan, 2013, The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein, PLoS Pathog, 9, e1003761, 10.1371/journal.ppat.1003761 · DOI
  45. Wang, 2016, Evolutionarily successful asian 1 dengue virus 2 lineages contain one substitution in envelope that increases sensitivity to polyclonal antibody neutralization, J Infect Dis, 213, 975, 10.1093/infdis/jiv536 · DOI
  46. Dowd, 2015, Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing, MBio, 6, e01559, 10.1128/mBio.01559-15 · DOI
  47. Zhang, 2005, Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence, J Virol, 79, 15123, 10.1128/JVI.79.24.15123-15130.2005 · DOI · Paper page
  48. Quiner, 2014, Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua, J Virol, 88, 13125, 10.1128/JVI.01822-14 · doi:10.1128/jvi.01822-14
  49. Adams, 2006, Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok, Proc Natl Acad Sci USA, 103, 14234, 10.1073/pnas.0602768103 · DOI · Paper page
  50. Bennett, 2006, Molecular evolution of dengue 2 virus in Puerto Rico: positive selection in the viral envelope accompanies clade reintroduction, J Gen Virol, 87, 885, 10.1099/vir.0.81309-0 · DOI
  51. Twiddy, 2002, Phylogenetic evidence for adaptive evolution of dengue viruses in nature, J Gen Virol, 83, 1679, 10.1099/0022-1317-83-7-1679 · DOI
  52. Cummings, 2005, Dynamic effects of antibody-dependent enhancement on the fitness of viruses, Proc Natl Acad Sci USA, 102, 15259, 10.1073/pnas.0507320102 · DOI · Paper page
  53. Recker, 2009, Immunological serotype interactions and their effect on the epidemiological pattern of dengue, Proc Biol Sci, 276, 2541
  54. Wearing, 2006, Ecological and immunological determinants of dengue epidemics, Proc Natl Acad Sci USA, 103, 11802, 10.1073/pnas.0602960103 · DOI · Paper page
  55. Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 · DOI · Paper page
  56. Durbin, 2013, A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial, J Infect Dis, 207, 957, 10.1093/infdis/jis936 · doi:10.1093/infdis/jis936
  57. Anderson, 2014, A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand, J Infect Dis, 209, 360, 10.1093/infdis/jit436 · DOI · Paper page
  58. Reich, 2013, Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity, J R Soc Interface, 10, 20130414, 10.1098/rsif.2013.0414 · DOI · Paper page
  59. Weiskopf, 2014, T-cell immunity to infection with dengue virus in humans, Front Immunol, 5, 93, 10.3389/fimmu.2014.00093 · DOI
  60. Corbett, 2015, Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort, J Infect Dis, 211, 590, 10.1093/infdis/jiu481 · doi:10.1093/infdis/jiu481
  61. Puschnik, 2013, Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans, PLoS Negl Trop Dis, 7, e2274, 10.1371/journal.pntd.0002274 · DOI
  62. Halstead, 1980, Transmission of dengue 1 and 2 viruses in Greece in 1928, Am J Trop Med Hyg, 29, 635, 10.4269/ajtmh.1980.29.635 · DOI
  63. Guzman, 2007, Neutralizing antibodies after infection with dengue 1 virus, Emerg Infect Dis, 13, 282, 10.3201/eid1302.060539 · DOI
  64. Halstead, 1962, Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea, Am J Hyg, 75, 190
  65. Hickey, 2013, Serotype-specific host responses in rhesus macaques after primary dengue challenge, Am J Trop Med Hyg, 89, 1043, 10.4269/ajtmh.13-0145 · DOI
  66. Koraka, 2007, Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses, Microbes Infect, 9, 940, 10.1016/j.micinf.2007.03.012 · doi:10.1016/j.micinf.2007.03.012
  67. Katzelnick, 2015, Dengue viruses cluster antigenically but not as discrete serotypes, Science, 349, 1338, 10.1126/science.aac5017 · DOI · Paper page
  68. Gibbons, 2007, Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences, Am J Trop Med Hyg, 77, 910, 10.4269/ajtmh.2007.77.910 · DOI · Paper page
  69. Rouvinski, 2015, Recognition determinants of broadly neutralizing human antibodies against dengue viruses, Nature, 520, 109, 10.1038/nature14130 · DOI · Paper page
  70. Sabin, 1952, Research on dengue during World War II, Am J Trop Med Hyg, 1, 30, 10.4269/ajtmh.1952.1.30 · DOI · Paper page
  71. Halstead, 1973, Studies on the immunization of monkeys against dengue I. Protection derived from single and sequential virus infections, Am J Trop Med Hyg, 22, 365, 10.4269/ajtmh.1973.22.365 · doi:10.4269/ajtmh.1973.22.365
  72. Halstead, 2013, Identifying protective dengue vaccines: guide to mastering an empirical process, Vaccine, 31, 4501, 10.1016/j.vaccine.2013.06.079 · doi:10.1016/j.vaccine.2013.06.079
  73. Bernardo, 2008, Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2, Clin Vaccine Immunol, 15, 439, 10.1128/CVI.00208-07 · doi:10.1128/cvi.00208-07
  74. Thomas, 2009, Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance, Am J Trop Med Hyg, 81, 825, 10.4269/ajtmh.2009.08-0625 · DOI · Paper page
  75. Mukherjee, 2014, Mechanism and significance of cell type-dependent neutralization of flaviviruses, J Virol, 88, 7210, 10.1128/JVI.03690-13 · DOI
  76. Pierson, 2007, The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection, Cell Host Microbe, 1, 135, 10.1016/j.chom.2007.03.002 · DOI · Paper page
  77. Plevka, 2014, Mechanism for maturation-related reorganization of flavivirus glycoproteins, J Struct Biol, 185, 27, 10.1016/j.jsb.2013.11.001 · doi:10.1016/j.jsb.2013.11.001
  78. Austin, 2012, Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope, PLoS Pathog, 8, e1002930, 10.1371/journal.ppat.1002930 · DOI
  79. Brien, 2010, Genotype-specific neutralization and protection by antibodies against dengue virus type 3, J Virol, 84, 10630, 10.1128/JVI.01190-10 · DOI
  80. Timiryasova, 2013, Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development, Am J Trop Med Hyg, 88, 962, 10.4269/ajtmh.12-0461 · doi:10.4269/ajtmh.12-0461
  81. Endy, 2004, Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand, J Infect Dis, 189, 990, 10.1086/382280 · DOI
  82. Buddhari, 2014, Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies, PLoS Negl Trop Dis, 8, e3230, 10.1371/journal.pntd.0003230 · DOI
  83. de Alwis, 2011, In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection, PLoS Negl Trop Dis, 5, e1188, 10.1371/journal.pntd.0001188 · DOI · Paper page
  84. Smith, 2013, The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein, MBio, 4, e00873, 10.1128/mBio.00873-13 · DOI · Paper page
  85. Tsai, 2015, Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies, J Virol, 89, 7348, 10.1128/JVI.00273-15 · doi:10.1128/jvi.00273-15
  86. Fibriansah, 2015, A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins, Nat Commun, 6, 6341, 10.1038/ncomms7341 · DOI · Paper page
  87. Fibriansah, 2014, A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface, EMBO Mol Med, 6, 358, 10.1002/emmm.201303404 · DOI · Paper page
  88. Fibriansah, 2015, Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers, Science, 349, 88, 10.1126/science.aaa8651 · DOI · Paper page
  89. Teoh, 2012, The structural basis for serotype-specific neutralization of dengue virus by a human antibody, Sci Transl Med, 4, 139ra83, 10.1126/scitranslmed.3003888 · DOI · Paper page
  90. de Alwis, 2012, Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions, Proc Natl Acad Sci USA, 109, 7439, 10.1073/pnas.1200566109 · DOI · Paper page
  91. Messer, 2016, Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1, J Virol, 90, 5090, 10.1128/JVI.00155-16 · doi:10.1128/jvi.00155-16
  92. Halstead, 1979, In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody, J Infect Dis, 140, 527, 10.1093/infdis/140.4.527 · DOI · Paper page
  93. Goncalvez, 2007, Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention, Proc Natl Acad Sci USA, 104, 9422, 10.1073/pnas.0703498104 · DOI · Paper page
  94. Zellweger, 2010, Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease, Cell Host Microbe, 7, 128, 10.1016/j.chom.2010.01.004 · DOI · Paper page
  95. Williams, 2013, Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected], PLoS Pathog, 9, e1003157, 10.1371/journal.ppat.1003157 · DOI
  96. Simmons, 2007, Maternal antibody and viral factors in the pathogenesis of dengue virus in infants, J Infect Dis, 196, 416, 10.1086/519170 · DOI · Paper page
  97. Chau, 2008, Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity, J Infect Dis, 198, 516, 10.1086/590117 · DOI · Paper page
  98. Chau, 2009, Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants, J Infect Dis, 200, 1893, 10.1086/648407 · DOI
  99. Kliks, 1988, Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants, Am J Trop Med Hyg, 38, 411, 10.4269/ajtmh.1988.38.411 · DOI · Paper page
  100. Clapham, 2015, Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics, PLoS Negl Trop Dis, 9, e0004262, 10.1371/journal.pntd.0004262 · doi:10.1371/journal.pntd.0004262
  101. Hammond, 2005, Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua, Am J Trop Med Hyg, 73, 1063, 10.4269/ajtmh.2005.73.1063 · DOI · Paper page
  102. Kliks, 1989, Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever, Am J Trop Med Hyg, 40, 444, 10.4269/ajtmh.1989.40.444 · DOI · Paper page
  103. Libraty, 2009, A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model, PLoS Med, 6, e1000171, 10.1371/journal.pmed.1000171 · DOI · Paper page
  104. Laoprasopwattana, 2005, Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection, J Infect Dis, 192, 510, 10.1086/431520 · doi:10.1086/431520
  105. Halstead, 2014, Dengue antibody-dependent enhancement: knowns and unknowns, Microbiol Spectr, 2, 249, 10.1128/microbiolspec.AID-0022-2014 · DOI · Paper page
  106. Amanna, 2010, Mechanisms that determine plasma cell lifespan and the duration of humoral immunity, Immunol Rev, 236, 125, 10.1111/j.1600-065X.2010.00912.x · DOI · Paper page
  107. Slifka, 2014, Vaccine-mediated immunity against dengue and the potential for long-term protection against disease, Front Immunol, 5, 195, 10.3389/fimmu.2014.00195 · DOI
  108. Dejnirattisai, 2015, A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus, Nat Immunol, 16, 785, 10.1038/ni0715-785a · doi:10.1038/ni0715-785a
  109. Purtha, 2011, Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants, J Exp Med, 208, 2599, 10.1084/jem.20110740 · DOI · Paper page
  110. Weiskopf, 2015, The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes, J Virol, 89, 120, 10.1128/JVI.02129-14 · DOI · Paper page
  111. Rothman, 2011, Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms, Nat Rev Immunol, 11, 532, 10.1038/nri3014 · DOI · Paper page
  112. Yauch, 2009, A protective role for dengue virus-specific CD8+ T cells, J Immunol, 182, 4865, 10.4049/jimmunol.0801974 · DOI · Paper page
  113. Hatch, 2011, Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection, J Infect Dis, 203, 1282, 10.1093/infdis/jir012 · DOI
  114. Weiskopf, 2013, Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells, Proc Natl Acad Sci USA, 110, E2046, 10.1073/pnas.1305227110 · DOI · Paper page
  115. Weiskopf, 2015, Human CD8+ T cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets, J Infect Dis, 212, 1743, 10.1093/infdis/jiv289 · DOI
  116. Guy, 2008, Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects, Vaccine, 26, 5712, 10.1016/j.vaccine.2008.08.019 · DOI
  117. Mangada, 2005, Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes, J Immunol, 175, 2676, 10.4049/jimmunol.175.4.2676 · DOI · Paper page
  118. Yauch, 2010, CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination, J Immunol, 185, 5405, 10.4049/jimmunol.1001709 · DOI · Paper page
  119. Weiskopf, 2015, Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity, Proc Natl Acad Sci USA, 112, E4256, 10.1073/pnas.1505956112 · DOI · Paper page
  120. Pagni, 2012, Evasion of the human innate immune system by dengue virus, Immunol Res, 54, 152, 10.1007/s12026-012-8334-2 · DOI
  121. Popper, 2012, Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children, PLoS Negl Trop Dis, 6, e1966, 10.1371/journal.pntd.0001966 · DOI
  122. Simmons, 2007, Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever, J Infect Dis, 195, 1097, 10.1086/512162 · DOI · Paper page
  123. Kwissa, 2014, Dengue virus infection induces expansion of a CD14+CD16+ monocyte population that stimulates plasmablast differentiation, Cell Host Microbe, 16, 115, 10.1016/j.chom.2014.06.001 · DOI · Paper page
  124. Koraka, 2001, Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection, J Clin Microbiol, 39, 4332, 10.1128/JCM.39.12.4332-4338.2001 · DOI
  125. Laoprasopwattana, 2007, Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication, J Infect Dis, 195, 1108, 10.1086/512860 · doi:10.1086/512860
  126. García, 2006, Antibodies from patients with dengue viral infection mediate cellular cytotoxicity, J Clin Virol, 37, 53, 10.1016/j.jcv.2006.04.010 · doi:10.1016/j.jcv.2006.04.010
  127. Avirutnan, 2006, Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement, J Infect Dis, 193, 1078, 10.1086/500949 · DOI · Paper page
  128. Markoff, 1991, Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection, J Infect Dis, 164, 294, 10.1093/infdis/164.2.294 · DOI
  129. Falconar, 1997, The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis, Arch Virol, 142, 897, 10.1007/s007050050127 · DOI · Paper page
  130. Lin, 2011, Molecular mimicry between virus and host and its implications for dengue disease pathogenesis, Exp Biol Med (Maywood), 236, 515, 10.1258/ebm.2011.010339 · DOI
  131. Chuang, 2014, Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis, J Virol, 88, 13759, 10.1128/JVI.02166-14 · DOI
  132. Chuang, 2013, Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities, Thromb Haemost, 110, 358, 10.1160/TH13-02-0149 · doi:10.1160/th13-02-0149
  133. Modhiran, 2015, Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity, Sci Transl Med, 7, 304ra142, 10.1126/scitranslmed.aaa3863 · DOI · Paper page
  134. Beatty, 2015, Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination, Sci Transl Med, 7, 304ra141, 10.1126/scitranslmed.aaa3787 · DOI · Paper page
  135. Puerta-Guardo, 2016, Dengue Virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability, PLoS Pathog, 12, e1005738, 10.1371/journal.ppat.1005738 · DOI · Paper page
  136. Vannice, 2015, Next generation dengue vaccines: a review of the preclinical development pipeline, Vaccine, 33, 7091, 10.1016/j.vaccine.2015.09.053 · doi:10.1016/j.vaccine.2015.09.053
  137. Sampath, 2013, Glycan masking of Plasmodium vivax Duffy binding protein for probing protein binding function and vaccine development, PLoS Pathog, 9, e1003420, 10.1371/journal.ppat.1003420 · DOI
  138. McLellan, 2011, Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus, J Mol Biol, 409, 853, 10.1016/j.jmb.2011.04.044 · DOI
  139. Guy, 2015, Dengue vaccine: hypotheses to understand CYD-TDV-induced protection, Nat Rev Microbiol, 14, 45, 10.1038/nrmicro.2015.2 · DOI · Paper page
  140. Plotkin, 2012, Nomenclature for immune correlates of protection after vaccination, Clin Infect Dis, 54, 1615, 10.1093/cid/cis238 · DOI · Paper page

Metadata

Authors
Katzelnick, L. C., Coloma, J., & Harris, E.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2017-03
Volume
17
Issue
3
Pages
e88-e100
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2587552077
Cited by
211
References
5
FWCI
20.03
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dengue: knowledge gaps, unmet needs, and research priorities. https://app.cochat.ai/papers/10.1016/s1473-3099(16)30473-x
The paper
Katzelnick, L. C., Coloma, J., & Harris, E. (2017). Dengue: knowledge gaps, unmet needs, and research priorities. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(16)30473-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.